The fight against antimicrobial resistance (AMR) is a burning topic in global health right now with an estimated 700,000 deaths per year. This number is expected to rise to 10 million deaths by 2050 if decisive action is not taken today by the global community. As a health journey partner, Sanofi recognizes the urgency to act.
It has developed a new app called Bact’Attack (in French) that aims to educate teenagers and children about the appropriate use of antibiotics – on show during Antibiotic Awareness Week 2018 – and is a founding member of the AMR Industry Alliance (Antimicrobial Resistance Industry Alliance).
Today the united action of the AMR Industry Alliance has taken the first step in making the fight against AMR a more tangible reality. A union of more than 100 companies in the life-sciences industry, the Alliance works closely with stakeholders to respond to the United Nations’ 2016 call for action. Its first report, released in January 2018, aims to track progress made by the life-sciences industry.Infotraphics
Collaboration is the way forward
The AMR Industry Alliance’s goal is not only to pro-actively address antimicrobial resistance in a multi-sectoral response, but also to take action against it. The report identifies best practices, opportunities, and gaps where further efforts may be required by industry and other stakeholders. More specifically, it provides unique insights into the practical steps that members are taking to respond to AMR in the areas of research and science, access, appropriate use, manufacturing and the environment. The report is based on data collected from a survey of 36 companies, which analyzed their strategies toward AMR-relevant products and what action they are taking against the crisis.
Charles Wells, representing Sanofi as a member of the AMR Industry Alliance Board, answers our question.
“The first AMR Industry Alliance Progress Report demonstrates the commitment of the research-based biopharmaceutical companies to bring much-needed positive momentum to curb AMR,” explains Thomas Cueni, Director General, IFPMA (the International Federation of Pharmaceutical Manufacturers & Associations). “Notwithstanding a challenging innovation environment and the current lack of economic incentives, the results of the report underline the crucial role of the private sector investments in research and development to respond to the challenges of AMR, with several antibiotics and vaccines currently in late stages of development.”
The report demonstrates the importance of partnerships and cross-sector collaboration - R&D biopharmaceutical companies, generics, SMEs, and diagnostics - but it also highlights that much more needs to be done.
“To deliver sustainable solutions, ensuring cooperation with all stakeholders, including governments and international organizations, is the only viable way forward in the fight against AMR,” says Cueni.
Find out what Sanofi did during Antibiotic Awareness Week 2017 in its commitment to the fight against microbial resistance (read more about it here).
Visit the AMR Industry Alliance website